News
Avacta announces clinical study of AVA6000
Pro-doxorubicin will advance to the fourth dose following a positive review of safety and tolerability
Avacta Group – which develops oncology drugs based on its Affimer and pre|CISION platforms – has announced that the first-in-human phase 1 trial of AVA6000 Pro-doxorubicin will advance to the fourth dose cohort of patients, following a positive review of safety and tolerability data.